Impax acquires generic drug portfolio from Teva; Teva returns rights to ANDA for generic Concerta
Impax Laboratories Inc. acquired a portfolio of 18 marketed, approved and pipeline generics from Teva Pharmaceutical Industries Ltd. and Allergan affiliates for $586mm (funded from $400mm in new term loans with the balance from cash on hand). The product divestitures were mandated by the FTC as a condition of Teva's pending acquisition of Allergan's global generics business (just last week Teva sold off the rights to eight ANDAs to Dr. Reddy's.)
- Generic Drugs
- Specialty Pharmaceuticals
- Controlled Release
- Marketing (Licensing)
- Product Purchase
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.